Neumora Therapeutics, Inc. financial data

Symbol
NMRA on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
490 Arsenal Way, Suite 200, Watertown, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 3, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.38K %
Debt-to-equity 7.82 %
Return On Equity -69 % -101%
Return On Assets -64 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 162M shares +1.95%
Common Stock, Shares, Outstanding 162M shares +1.81%
Entity Public Float 824M USD
Common Stock, Value, Issued 16K USD 0%
Weighted Average Number of Shares Outstanding, Basic 159M shares +145%
Weighted Average Number of Shares Outstanding, Diluted 159M shares +145%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 201M USD +40.8%
General and Administrative Expense 62.5M USD +37.5%
Operating Income (Loss) -263M USD -4.51%
Nonoperating Income (Expense) 19.9M USD +20.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -72.5M USD -36.7%
Income Tax Expense (Benefit) 53K USD
Net Income (Loss) Attributable to Parent -244M USD -3.33%
Earnings Per Share, Basic -1.53 USD/shares +57.9%
Earnings Per Share, Diluted -1.53 USD/shares +57.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 142M USD -62%
Marketable Securities, Current 165M USD +107%
Assets, Current 314M USD -34.3%
Property, Plant and Equipment, Net 1.14M USD -36.3%
Operating Lease, Right-of-Use Asset 1.78M USD -64.9%
Assets 317M USD -36.1%
Accounts Payable, Current 3.31M USD +881%
Employee-related Liabilities, Current 9.98M USD -0.36%
Accrued Liabilities, Current 24.6M USD +15.7%
Liabilities, Current 29.9M USD +19%
Operating Lease, Liability, Noncurrent 938K USD
Liabilities 29.9M USD +10.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax 62K USD
Retained Earnings (Accumulated Deficit) -947M USD -34.7%
Stockholders' Equity Attributable to Parent 287M USD -38.8%
Liabilities and Equity 317M USD -36.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -43M USD -30%
Net Cash Provided by (Used in) Financing Activities 1.85M USD +1727%
Net Cash Provided by (Used in) Investing Activities -150M USD -5425%
Common Stock, Shares Authorized 700M shares 0%
Common Stock, Shares, Issued 162M shares +1.81%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -191M USD -534%
Deferred Tax Assets, Valuation Allowance 264M USD +34%
Deferred Tax Assets, Gross 265M USD +33.3%
Operating Lease, Liability 5.23M USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -244M USD -3.58%
Lessee, Operating Lease, Liability, to be Paid 1.89M USD -66.3%
Property, Plant and Equipment, Gross 3.19M USD -1.12%
Operating Lease, Liability, Current 1.85M USD -45.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.89M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 1.89M USD -49.1%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 39K USD -89.7%
Deferred Tax Assets, Operating Loss Carryforwards 112M USD +41.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 50M shares 0%
Unrecognized Tax Benefits 9.68M USD +11.7%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 158K USD 0%
Deferred Tax Assets, Net of Valuation Allowance 538K USD -64.1%
Share-based Payment Arrangement, Expense 40M USD +132%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%